The BRCA-AI system, recognized among the top projects at the Harvard Medical School competition, was presented in Astana during a Swiss Institute of Technology and Entrepreneurship (SITE) module for healthcare professionals.
Daniel Martinez Canca, an oncology researcher and professor at the Swiss Institute of Technology and Entrepreneurship (SITE), has presented BRCA-AI in Kazakhstan—an innovative AI startup designed for the early detection and personalized treatment of breast cancer.
The presentation took place in Astana as part of a specialized SITE educational module for healthcare representatives. The expert delivered a presentation titled “AI in Healthcare: New Technologies, Management, and the Future of Medicine,” discussing the practical application of artificial intelligence in medicine and sharing international experience in implementing innovative solutions.
Daniel Martinez Canca is the CEO of ESEMED Healthcare, an oncology researcher, and an international expert in healthcare strategy, marketing, and the implementation of AI solutions in medicine. Throughout his career, he has executed projects across markets in the US, Europe, Latin America, Asia, and Africa.
“The point is not simply to have AI tools in your company, but to use artificial intelligence correctly. If applied improperly, it can only increase the number of erroneous decisions. The implementation of AI is only possible when there is high-quality data and validated research results,” noted Daniel Martinez Canca.
During his address, the expert highlighted several international case studies. In Rwanda, for instance, medical drones have completed over a million flights, delivering medicines and blood plasma to remote areas of the country.
Particular attention was paid to the BRCA-AI project—an artificial intelligence-based platform designed to combat triple-negative breast cancer, one of the most aggressive forms of oncological disease.
The system analyzes patient biomarkers and clinical data, helping physicians select personalized treatment protocols. It also predicts the risk of complications and assesses the potential efficacy of drugs before therapy begins.
In late 2025, BRCA-AI secured second place among more than 700 international projects at the Harvard Medical School competition, emerging as one of the most promising AI solutions in oncology. Currently, the startup is transitioning from the scientific validation phase to commercial implementation.
The presentation of the project was supported by the Swiss Institute of Technology and Entrepreneurship (SITE)—a Swiss AI-focused university that is actively expanding its presence in Central Asia and the Caucasus.
One of the university’s key development areas is building an ecosystem for tech entrepreneurs. Students and program participants not only learn about cutting-edge technologies but also work on their own startups, presenting them to international experts and potential investors.
The university places special emphasis on Executive MBA programs in healthcare, which cover the digital transformation of medicine, AI implementation, healthcare organization management, and the commercialization of innovative developments.